Jason I Kass1,2, Laureano Giraldez2, William Gooding3, Garret Choby1, Seungwon Kim1, Brett Miles2, Marita Teng2, Andrew G Sikora4, Jonas T Johnson1, Eugene N Myers1, Umamaheswar Duvvuri1,5, Eric M Genden2, Robert L Ferris6. 1. Department of Otolaryngology, University of Pittsburgh Medical Center Pittsburgh, Pennsylvania. 2. Department of Otolaryngology, Icahn School of Medicine at Mount Sinai, New York, New York. 3. Biostatistics Facility, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania. 4. Department of Otolaryngology, Baylor College of Medicine, Houston, Texas. 5. Veterans Affairs Pittsburgh Health System, Pittsburgh, Pennsylvania. 6. Department of Otolaryngology, University of Pittsburgh Medical Center Pittsburgh, Pennsylvania. ferrisrl@upmc.edu.
Abstract
BACKGROUND: The purpose of this study was to characterize oncologic outcomes in early (T1-T2, N0) and intermediate (T1-T2, N1) oropharyngeal squamous cell carcinoma (SCC) after surgery. METHODS: Patients with oropharyngeal SCC treated with surgery were identified from 2 academic institutions. RESULTS: Of 188 patients, 143 met the inclusion criteria. Eighty-six (60%) had T1 to T2 N0 and 57 (40%) had T1 to T2 N1 disease. Sixty-five patients (45%) underwent a robotic-assisted resection, whereas the remaining had transoral (n = 60; 42%), mandible-splitting (n = 11; 8%), or transhyoid approaches (n = 7; 5%). Human papillomavirus (HPV) status was known for 97 patients (68%), and 54 (55%) were HPV positive. Three-year recurrence-free survival (RFS) was 82% (95% confidence interval [CI] = 0.75-0.89). Since 2008, HPV infection was protective of recurrence (log-rank p = .0334). A single node did not increase the risk of recurrence (p = .467) or chance of a second primary (p = .175). CONCLUSION: Complete surgical resection is effective therapy for early and intermediate oropharyngeal SCC. HPV-negative patients were at increased risk for locoregional recurrence or second primary disease.
BACKGROUND: The purpose of this study was to characterize oncologic outcomes in early (T1-T2, N0) and intermediate (T1-T2, N1) oropharyngeal squamous cell carcinoma (SCC) after surgery. METHODS:Patients with oropharyngeal SCC treated with surgery were identified from 2 academic institutions. RESULTS: Of 188 patients, 143 met the inclusion criteria. Eighty-six (60%) had T1 to T2 N0 and 57 (40%) had T1 to T2 N1 disease. Sixty-five patients (45%) underwent a robotic-assisted resection, whereas the remaining had transoral (n = 60; 42%), mandible-splitting (n = 11; 8%), or transhyoid approaches (n = 7; 5%). Human papillomavirus (HPV) status was known for 97 patients (68%), and 54 (55%) were HPV positive. Three-year recurrence-free survival (RFS) was 82% (95% confidence interval [CI] = 0.75-0.89). Since 2008, HPV infection was protective of recurrence (log-rank p = .0334). A single node did not increase the risk of recurrence (p = .467) or chance of a second primary (p = .175). CONCLUSION: Complete surgical resection is effective therapy for early and intermediate oropharyngeal SCC. HPV-negative patients were at increased risk for locoregional recurrence or second primary disease.
Authors: Xu Qian; Branko Sinikovic; Frank Schreiber; Sebastian Ochsenreither; Konrad Klinghammer; Barbara Wollenberg; Andreas M Kaufmann; Andreas E Albers Journal: Eur Arch Otorhinolaryngol Date: 2018-08-29 Impact factor: 2.503
Authors: Kevin Motz; Hsien-Yen Chang; Harry Quon; Jeremy Richmon; David W Eisele; Christine G Gourin Journal: JAMA Otolaryngol Head Neck Surg Date: 2017-06-01 Impact factor: 6.223